| CVD HR (95%CI) | Hard CVD HR (95%CI) | ||||
---|---|---|---|---|---|---|
E/N | Model 1 | Model 2 | E/N | Model 1 | Model 2 | |
FPG-WHO (mmol/L) | ||||||
  < 6.1 | 169/327 | 1.00 | 1.00 | 66/327 | 1.00 | 1.00 |
 6.1–6.9 | 21/44 | 0.92 (0.58–1.45) | 0.87 (0.55–1.39) | 10/44 | 1.13 (0.58–2.21) | 0.97 (0.49–1.93) |
  ≥ 7 | 30/37 | 2.02 (1.36–3.00) | 2.07 (1.39–3.12) | 13/37 | 1.95 (1.07–3.53) | 2.02 (1.07–3.80) |
FPG-ADA (mmol/L) | ||||||
  < 5.6 | 129/253 | 1.00 | 1.00 | 45/253 | 1.00 | 1.00 |
 5.6–6.9 | 61/118 | 1.07 (0.79–1.46) | 1.05 (0.77–1.44) | 31/118 | 1.62 (1.03–2.57) | 1.52 (0.95–2.45) |
  ≥ 7 | 30/37 | 2.09 (1.40–3.12) | 2.15 (1.41–3.27) | 13/37 | 2.28 (1.23–4.22) | 2.41 (1.25–4.67) |
2Â h-PCPG (mmol/L) | ||||||
  < 7.8 | 123/240 | 1.00 | 1.00 | 50/240 | 1.00 | 1.00 |
 7.8–11.0 | 54/105 | 1.01 (0.73–1.39) | 0.97 (0.70–1.36) | 20/105 | 0.93 (0.55–1.56) | 0.90 (0.53–1.55) |
  ≥ 11 | 43/63 | 1.48 (1.04–2.10) | 1.46 (1.02–2.11) | 19/63 | 1.59 (0.93–2.70) | 1.54 (0.88–2.70) |